Skip to main content
. 2019 Apr 3;17(6):5193–5200. doi: 10.3892/ol.2019.10207

Figure 4.

Figure 4.

Differences in the expression of miRs depending on PD-L1 expression status in the tumor cells of patients with non-small cell lung cancer. (A) Higher relative expression of miR-200b in the group with ≥1% (n=24) compared with the group with <1% (n=18) tumor positive cells (TC, SP142). (B) Higher relative expression of miR-200b in the group with ≥5% (n=14) compared with the group with <5% (n=28) tumor positive cells (TC, SP142). (C) Higher relative expression of miR-141 in the group with ≥5% (n=15) compared with the group with <5% (n=28) tumor positive cells (TC, SP142). (D) Higher relative expression of miR-141 in the group with ≥50% (n=18) compared with the group with <50% (n=21) tumor positive cells (TC, 22C3). (E) Higher relative expression of miR-429 in the group with ≥1% (n=21) compared with the group with <1% (n=20) tumor positive cells (SP142). (F) Higher relative expression of miR-429 in the group with ≥10% (n=14) compared with that with <10% (n=27) tumor positive cells (SP142). PD-L1, programmed death ligand 1; miR/miRNA, microRNA; TC, tumor cells.